BioSpace News Archive

SpringWorks Therapeutics, Inc. announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Eitan Group announced a service partnership with InfuSystem Holdings, Inc., a leading national provider of infusion pumps and related services for the healthcare industry in the U.S. and Canada.

On 29 August 2019, the World Artificial Intelligence Conference opened in Shanghai World Expo Center and Expo Exhibition Hall.

Avanos Medical, Inc. announced that Joe Woody, chief executive officer, will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt hotel in New York on Monday, Sept. 9 at approximately 1:40 p.m., ET.

ArisGlobal, LLC, a leading provider of life sciences software that automates core drug development functions for over 250 life sciences companies, will present a session titled “How to Fully Leverage Automation in PV – A Real Case Study” at the upcoming World Drug Safety Congress Europe 2019, September 10-11, 2019 at the Hotel Hilton Amsterdam, Amsterdam, Netherlands.

Application suites for clinical, regulatory, and quality enable organizations to speed drug development

Bausch Health Companies Inc. announced that the Company will participate in three investor conferences.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it is planning a proof of concept (POC) clinical trial for the use of its RAP technology for the treatment of keloid and hypertrophic scars.

Citius Pharmaceuticals, Inc. (“Citius”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will be presenting at the 4th annual Disruptive Growth Conference on Wednesday, September 4th at 3:40PM EST in Presentation Room A/B.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 21st Annual Global Investment Conference to be held in New York, NY on September 8th-10th.